I wonder why there are significant references to Severe HTG in the PR? That’s the Marine label that the generics are approved for. It’s only ~7-10% of the IPE market so there’s some reason why they are highlighting this indication, but I can’t figure it out. Perhaps it’s simply to highlight that Amarin has an approved drug to reduce sHTG and target this at risk population. But why promote/advertise this indication when the vast majority of scripts would go to generics.
Market Data 
Markets 
AI
